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IMRT is a technique that adds fluence modulation to beam 
shaping, which improves radiotherapy dose conformity 
around the tumour and spares surrounding normal structures. 
Treatment with IMRT is becoming more widely available for 
the treatment of lung cancer, despite the paucity of high 
level evidence supporting the routine use of this more 
resource intense and complex technique [Chan. J Thor Oncol 
2014]. It allows the treatment of patients with large volume 
disease, close to critical organs at risk with curative doses.  
Very few prospective trials have reported on the use of IMRT. 
RTOG 0617 was a 2 x 2 factorial design study, in which 
patients with stage III NSCLC were randomized to receive 
high dose (74 Gy in 37 fractions) or standard dose (60 Gy in 
30 fractions) RT concurrently with weekly 
paclitaxel/carboplatin with or without cetuximab [Bradley. 
Lancet Oncol 2015]. The radiotherapy technique (3D 
conformal RT vs IMRT) was a stratification factor. 
Disappointingly, there was a significant increase in the risk of 
death in the high-dose arms (median survival, 19.5 months vs 
28.7 months; p=0.0007), and a 37% increase in the risk of 
local failure in the high-dose arms (hazard ratio, 1.37; 
p=0.0319). It should be noted that just under half of the 
patients in this study were treated with IMRT (46.5%). 
Although patients were stratified by treatment delivery 
technique and the proportions of patients treated with IMRT 
were balanced between treatment groups (46.1% in 60 Gy 
arms and 47.1% in 74 Gy arms), the delivery of 74 Gy was 
probably challenging, particularly in patients treated without 
IMRT, given the gross tumour volume (GTV) (mean 124.7 in 60 
Gy arms and 128.5 cc in 74 Gy arms).  
A subsequent analysis on patient reported outcome 
demonstrated a significantly worse quality of life on the 74 
Gy arms at 3 months after treatment [Mosvas JAMA 1015]. 
Interestingly, despite minimal differences in clinician-
reported side-effects between treatment arms, the decline in 
quality of life was significantly reduced with the use of IMRT 
compared to 3DCRT suggesting that the use of improved 
radiotherapy treatment techniques may be beneficial. 
Furthermore, baseline QOL was an independent prognostic 
factor for survival. A further analysis of RTOG0617 compared 
the outcome of patients treated with 3D-conformal and 
intensity modulated radiotherapy [Chun. ASTRO 2015]. 
Survival was the same in both groups in spite of the larger 
proportion of patients with stage IIIb vs IIIa and larger 
Planning Target Volume in the IMRT cohort. Moreover the use 
of IMRT reduced severe pneumonitis, dose delivered to the 
heart and more patients received chemotherapy in the IMRT 
cohort. 
Population-based studies have not shown any significant 
difference in overall survival, toxicity or time spent 
hospitalized following treatment between 3DCRT and IMRT 
[Harris. Int J Radiat Oncol Biol Phys 2014; Chen. J Thorac 
Oncol 2014]. The need remains to develop clinical trials that 
will demonstrate the benefit of IMRT in terms of toxicity, 
local control, survival or quality of life.  
A number of clinical trials are currently recruiting patients. 
Some are evaluating personalized dose escalation based on 
dose delivered to organs at risk (NCT01836692, NCT01166204) 
and others an increase dose to selected parts within the 
tumour, defined by functional imaging (Dose Painting) 
(NCT01024829, NCT01507428).  
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In countries with active mammography screening programs, 
the majority of breast cancers are diagnosed at an early 
stage. Those patients are treated with breast conserving 
surgery followed by adjuvant radiotherapy, which is 
equivalent to mastectomy in term of survival. The objective 
of the radio-surgical association is hence primarily cosmetic. 
Since those patients have excellent outcomes, it is logical to 
minimise any detrimental effects of the treatment, in term 
of acute and delayed side effects.  
Intensity Modulated Radiation Therapy (IMRT) is a radiation 
technique where the photon beam intensity is modulated 
across multiple irradiation fields to achieve a pre-determined 
goal for the dose distribution, using try and error methods. 
The goal can be to improve the conformality of the dose 
distribution or, as it is often the case for the breast, its 
homogeneity.  
There are many cohort studies and randomised clinical trials 
reporting on the clinical benefit for BIMRT used to improve 
the dose distribution homogeneity in the breast. A 
multicentre randomised controlled trial from Canada has 
demonstrated a large and significant reduction of acute skin 
toxicity, notably the moist desquamation occurring on the 
infra-mammary fold. This benefit was not present for large 
breasted patients. Moist desquamation was significantly 
associated with a severe pain and a reduction of Health 
Related Quality of Life (HRQoL). There are several studies 
reporting significant associations between the occurrence of 
moist desquamation and delayed side effects like 
telangiectasia and induration. Several randomised trials have 
also evaluated the impact of BIMRT on long-term side effect, 
and two studies from the UK using hypofractionated regimen 
showed a small but significant improvement of the cosmetic 
outcome at 5 years. It is important to note that no cosmetic 
improvement was found at 8 years in the Canadian study 
using conventional fractionation of 50 Gy in 25 treatments. In 
the Cambridge and Canadian studies there was no impact of 
the radiation technique on the long-term HRQoL. In the 
Canadian study there was a highly significant correlation 
between the initial pain experience at time of radiotherapy 
and the occurrence of chronic pain and a reduction in HRQoL 
at 8 years. Also the occurrence of moist desquamation at the 
time of radiation treatment was significantly correlated with 
the occurrence of telangiectasia, fibrosis and a poorer 
cosmetic outcome on self-evaluation questionnaire. Those 
studies suggest a complex interplay between the breast 
volume, the dose-fractionation schedule and the radiation 
technique. More recently, a study from Ghent demonstrated 
that for large breasted patients hypofractionated prone 
BIMRT significantly reduces moist desquamation compared to 
hypofractionated supine BIMRT.  
In summary, there are solid evidences to suggest that BIMRT 
reduces the occurrence of acute skin toxicity, including moist 
desquamation and pain. For large breasted women, the use 
of a prone technique BIMRT appears to significantly reduce 
moist desquamation. In regards to long-term side effect it 
seems that BIMRT could improve the cosmetic outcome when 
using hypofractionation, but its role is less clear when using a 
standard dose-fractionation regimen. A painful experience of 
moist desquamation during the initial radiation treatment is 
significantly associated with chronic pain and poorer HRQoL. 
Since BIMRT is a technique relatively simple to implement at 
no cost, outside the USA, it should be used as standard for 
adjuvant breast radiotherapy. 
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Most image guidance strategies today aim at minimizing 
random and/or systematic geometrical uncertainties by 
offline or online correction protocols based on either 
